Genflow Biosciences plc reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was GBP 1.34 million. Basic loss per share from continuing operations was GBP 0.00457.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.05 GBX | +1.67% | +12.96% | +114.04% |
05-30 | Genflow Biosciences receives 50% of grant for sarcopenia project | AN |
05-30 | Genflow Biosciences Secures Grant for Sarcopenia Research Program | MT |
1st Jan change | Capi. | |
---|---|---|
+114.04% | 13.57M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- GENF Stock
- News Genflow Biosciences plc
- Genflow Biosciences plc Reports Earnings Results for the Full Year Ended December 31, 2022